Guideline Panel Meeting: Overactive Bladder (2023)

Clinical Practice Guidelines Panel Meeting. Panelists will meet for two days to evaluate the evidence report and craft statements for the AUA guideline based on this evidence. By the end of the two days, the panel will come to a consensus on the group of evidence-based statements and supporting text that will form the new AUA Guideline on Overactive Bladder.

Target Audience

This activity is limited to OAB Guidelines Panel Members only. 

Learning Objectives

After completing this activity, participants will be able to:

  1. Analyze the latest scientific evidence for the diagnosis and management of OAB.
  2. Recommend appropriate diagnostic and treatment options for OAB.
  3. Apply improved critical thinking skills to medical literature reviews. 
Course summary
Available credit: 
  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Non-Physician Participation
Course opens: 
Course expires: 

Sunday, October 1, 2023     

10:00   Welcome and Introductions                                        Anne Cameron, MD

  Ariana Smith, MD

10:10   COI Policy & Panel Disclosures                                    Leila Rahimi, MHS

10:20   Timeline and Schedule                                                  Leila Rahimi, MHS           

10:30   Evidence Report Presentation                                     Lesley Souter, PhD    

11:30   Statement Review and Discussion                                                    

             11:30 – 1:00        Group One                                        Drs. Ginsberg & Dielubanza

1:00     Break                                                     

             1:30 – 3:00           Group Two                                        Drs. Rovner & Takacs  

             3:00 – 4:30           Group Three                                     Drs. Suskind & Reynolds

4:30     Meeting Adjourned             

Monday, October 2, 2023

10:00   Statement Review and Discussion      

10:00 -11:30       Group Four                                       Drs. Enemchukwu & Welk

               11:30 – 1:00       Group Five                                        Dr. Chung

1:00     Break

1:30     Statement Review and Discussion

             1:30 – 3:00           Group Six                                          Drs. Helfand & Linder

3:00     Next Steps                                                                        Leila Rahimi, MHS

3:30     Meeting Adjourned                                                                


The Overactive Bladder (OAB) Guidelines Panel have the following disclosures. 

NameCompany NameRelationship TypeFinancialEnd Date
Chung, Doreen EleanorSpineXScientific Study or TrialNoCurrent
Chung, Doreen EleanorAbbvieScientific Study or TrialNoCurrent
Dielubanza, Elodi J.None   
Enemchukwu, EkeneUrovantScientific Study or TrialNoCurrent
Enemchukwu, EkeneAvationScientific Study or TrialNo12/01/2022
Enemchukwu, EkeneBoston ScientificConsultant or AdvisorYesCurrent
Enemchukwu, EkeneAbbvieConsultant or AdvisorYes06/08/2022
Enemchukwu, EkeneAbbvieScientific Study or TrialNoCurrent
Enemchukwu, EkeneValenciaOther-Chair of DSMBYesCurrent
Enemchukwu, EkeneJournal of UrologyOther-Editorial BoardNoCurrent
Enemchukwu, EkeneNIH NIDDKOther-Research FundingNoCurrent
Enemchukwu, EkeneNeurourology and UrodynamicsOther-Editorial BoardNoCurrent
Ginsberg, David AlanProceptScientific Study or TrialNo09/20/2022
Ginsberg, David AlanNeurourology and UrodynamicsHealth PublishingNoCurrent
Ginsberg, David AlanSociety of Urodynamics, Female Pelvic Medicine & ULeadership PositionNoCurrent
Ginsberg, David AlanUrovantConsultant or AdvisorYes12/02/2021
Ginsberg, David AlanUrovantScientific Study or TrialNo12/31/2022
Ginsberg, David AlanCalderaConsultant or AdvisorYesCurrent
Ginsberg, David AlanAvationConsultant or AdvisorYes09/17/2022
Ginsberg, David AlanMedtronicMeeting Participant or LecturerYes09/20/2022
Helfand, Brian T.Exact SciencesMeeting Participant or LecturerYes01/01/2023
Helfand, Brian T.AmbryConsultant or AdvisorYes12/31/2021
Helfand, Brian T.Exact SciencesOther-ResearcherYes07/31/2022
Helfand, Brian T.Blue Earth DiagnosticsMeeting Participant or LecturerYesCurrent
Helfand, Brian T.Blue Earth DiagnosticsConsultant or AdvisorYes07/31/2022
Helfand, Brian T.GoPathConsultant or AdvisorYesCurrent
Helfand, Brian T.ProceptConsultant or AdvisorYesCurrent
Helfand, Brian T.NIDDK NIHScientific Study or TrialNoCurrent
Helfand, Brian T.UrovantScientific Study or TrialNo06/01/2023
Helfand, Brian T.AngiodynamicsScientific Study or TrialNoCurrent
Helfand, Brian T.ZenflowScientific Study or TrialNo12/31/2023
Helfand, Brian T.OlympusScientific Study or TrialNo01/31/2024
Linder, Brian J.MedtronicConsultant or AdvisorYes04/02/2022
Linder, Brian J.MedtronicScientific Study or TrialNoCurrent
Linder, Brian J.MedtronicScientific Study or TrialNoCurrent
Linder, Brian J.Neurourology and UrodyanmicsOther-Editorial Board memberNoCurrent
Linder, Brian J.National Institutes of HealthScientific Study or TrialNoCurrent
Pelletier Cameron, Anne K.MedtronicScientific Study or TrialNo05/25/2022
Pelletier Cameron, Anne K.AxonicsConsultant or AdvisorYes02/05/2022
Pelletier Cameron, Anne K.WileyHealth PublishingYes12/31/2025
Pelletier Cameron, Anne K.SpringerHealth PublishingYesCurrent
Pelletier Cameron, Anne K.NIDDKScientific Study or TrialNoCurrent
Pelletier Cameron, Anne K.SUFULeadership PositionNoCurrent
Pelletier Cameron, Anne K.SWIULeadership PositionNo05/15/2024
Reynolds, William StuartNIH NIDDKOther-Research GrantYesCurrent
Reynolds, William StuartSUFULeadership PositionNoCurrent
Reynolds, William StuartSUFUOther-Research GrantNoCurrent
Reynolds, William StuartNeurourology & UrodynamicsHealth PublishingNoCurrent
Rovner, Eric ScottAllerganConsultant or AdvisorYesCurrent
Rovner, Eric ScottMedtronicsConsultant or AdvisorYesCurrent
Rovner, Eric ScottNextMedOwner (Medical Pratice/ESWL Company)YesCurrent
Rovner, Eric ScottUrovantScientific Study or TrialYesCurrent
Rovner, Eric ScottBluewindConsultant or AdvisorYesCurrent
Rovner, Eric ScottHologixConsultant or AdvisorYesCurrent
Rovner, Eric ScotturomedicaScientific Study or TrialYes04/04/2023
Rovner, Eric ScottValenciaConsultant or AdvisorYesCurrent
Rovner, Eric ScottConvatecScientific Study or TrialNoCurrent
Rovner, Eric ScottAvationConsultant or AdvisorYesCurrent
Rovner, Eric ScottBoston ScientificMeeting Participant or LecturerYesCurrent
Rovner, Eric ScottAxonicsConsultant or AdvisorYesCurrent
Rovner, Eric ScottEG-427Consultant or AdvisorYesCurrent
Rovner, Eric ScottIronwoodScientific Study or TrialYesCurrent
Rovner, Eric ScottNational Association for ContinenceLeadership PositionNoCurrent
Rovner, Eric ScottSynapse ICConsultant or AdvisorYesCurrent
Rovner, Eric ScottViveveConsultant or AdvisorYes04/04/2023
Rovner, Eric ScottUrocureStock OptionYesCurrent
Smith, Ariana L.SUFULeadership PositionNoCurrent
Smith, Ariana L.Wiley Neurolurology and UrodynamicsLeadership PositionNoCurrent
Smith, Ariana L.NIDDKScientific Study or TrialYesCurrent
Smith, Ariana L.NICHDScientific Study or TrialYesCurrent
Smith, Ariana L.Pennsylvania Department of StateScientific Study or TrialYesCurrent
Suskind, Anne M.FlumeConsultant or AdvisorYesCurrent
Suskind, Anne M.Solv WellnessMeeting Participant or LecturerYes04/01/2022
Suskind, Anne M.SUFULeadership PositionNoCurrent
Suskind, Anne M.Neurourology and UrodynamicsHealth PublishingNoCurrent
Suskind, Anne M.Journal of UrologyHealth PublishingYesCurrent
Suskind, Anne M.Urology PracticeHealth PublishingNoCurrent
Suskind, Anne M.Society of Women in UrologyLeadership PositionNoCurrent
Suskind, Anne M.AHRQConsultant or AdvisorNo02/01/2026
Suskind, Anne M.Internatinoal Continence Society (ICS)Leadership PositionNo09/01/2023
Takacs, Elizabeth BroghammerMedtronicScientific Study or TrialYesCurrent
Takacs, Elizabeth BroghammerNorth Central Section of the AUALeadership PositionNoCurrent
Welk, Blayne KailiBDConsultant or AdvisorYes03/31/2022
Welk, Blayne KailiZenflowScientific Study or TrialNoCurrent

AUA Staff have nothing to disclose.

All relevant financial relationships have been mitigated.

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 11.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Non-Physician Participation
Please login or register to take this course.

Registration for this activity is limited to OAB Guideline Panel Members only.